Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)

GPCR · MARKET VIEW

Market view · as of Jul 20, 2026

Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-0.35
vs $-0.33 est · miss
52-wk position
41.6%
-48.3% vs 52w high · +7.7% 1mo

Price (last ~year)

Structure Therapeutics (GPCR) is a clinical-stage biopharmaceutical company developing oral therapeutics, currently carrying a $3.45 billion market capitalization. As of March 31, 2026, the firm maintains $316.2 million in cash against $5.8 million in total debt, while reporting $0 in TTM revenue and a $76.2 million net loss for the first quarter. Shares closed at $48.48, up 5.3% on the day, following recent conference presentations regarding its GLP-1 and amylin pipeline and reported insider share sales.

Valuation

Market cap
$3.45B
P/B
2.382
EV/EBITDA
-13.46
Beta
-1.569
Analyst target
$104.59

Quality & returns

Operating margin
0.0%
Profit margin
0.0%
ROE
-15.0%
ROA
-11.6%

Price movement

Last
$48.48
1-month
+7.7%
3-month
+3.5%
RSI (14)
47
vs SMA200
-4.8%
52-wk position
41.6% -48.3% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-03-31$0$-89.6M$-76.2M$-74.8M
2025-12-31$0$24.0M$33.0M$33.6M
2025-09-30$0$-73.8M$-65.7M$-65.3M
2025-06-30$0$-70.5M$-61.7M$-61.2M

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots